Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06680427 · ClinicalTrials.gov registry record · NA
Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study
A NA study of Aortic Stenosis Symptomatic, sponsored by MiRus.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 8
- Study locations
NCT06680427 is a NA study of Aortic Stenosis Symptomatic that is active but no longer recruiting, run by MiRus. The registered enrollment target is 30 participants. The trial reports 8 study locations across 7 states.
The verdict
NCT06680427, a NA study of Aortic Stenosis Symptomatic, is active but no longer recruiting, sponsored by MiRus.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 8
- Study locations
Study Summary
The Siegel™ Transcatheter Aortic Valve (TAVR) early feasibility study objective is to assess the acute and long-term safety and feasibility of the Siegel TAVR device in adult subjects with symptomatic, severe native aortic stenosis eligible for the transcatheter aortic valve replacement.
Conditions Studied
Interventions
- DEVICE Siegel Transcatheter Aortic Valve (TAVR)
Study Locations (8)
California
- Cedars-Sinai Medical Center - Los Angeles
- Stanford - Palo Alto
Florida
- NCH Healthcare System - Naples
Georgia
- Piedmont Healthcare - Atlanta
Minnesota
- Mayo Clinic - Rochester
New Jersey
- Atlantic Health System - Morristown
New York
- Columbia University Medical Center/ NYPH - New York
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-03-26 |
| Est. Completion | 2025-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06680427
The ClinicalTrials.gov registry entry for NCT06680427 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MiRus, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Aortic Stenosis Symptomatic appearing as the primary indexed condition, and to 1 intervention - of which Siegel Transcatheter Aortic Valve (TAVR) is the first listed.
NCT06680427 reports 8 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06680427 about?
NCT06680427 is a clinical study titled "Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study". The Siegel™ Transcatheter Aortic Valve (TAVR) early feasibility study objective is to assess the acute and long-term safety and feasibility of the Siegel TAVR device in adult subjects with symptomatic, severe native aortic stenosis eligible for the transcatheter aortic valve replacement.
What is the current status of trial NCT06680427?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-03-26. Estimated completion is 2025-12.
What conditions does trial NCT06680427 study?
This clinical trial studies the following conditions: Aortic Stenosis Symptomatic.
What interventions are being tested in trial NCT06680427?
The interventions under investigation include: Siegel Transcatheter Aortic Valve (TAVR) (DEVICE).
Who is sponsoring clinical trial NCT06680427?
This trial is sponsored by MiRus, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06680427 being conducted?
This trial has 8 study locations across California, Florida, Georgia, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.